attenuate the strain further, we constructed mutants with a deletion in the viral thymidine kinase gene. One mutant strain, designated 783, has a deletion of 19 base pairs and was shown to be highly immunogenic and safe for vaccination of pigs against pseudorabies virus.
Pseudorabies virus (PrV), an alphaherpesvirus, causes Aujeszky's disease in domestic and wild animals. In pigs, the natural host of the virus, PrV may induce an acute and sometimes fatal nervous condition (for a recent review see Pensaert & Kluge, 1989) . The disease is distributed world-wide and has growing impact on the pig industry.
One strategy to eradicate Aujeszky's disease relies on the use of a live vaccine that carries a serological marker enabling vaccinated animals to be distinguished from animals infected with virulent PrV strains (van Oirschot et al., 1986 (van Oirschot et al., , 1988 . In an earlier report, we described the construction of the attenuated PrV strain 2.4N3A (Quint et al., 1987) . This strain has a deletion of 2055 bp in the unique short (Us) region of the genome. As a result, the gI gene is deleted. In addition, it has small deletions of about 100 bp in the inverted repeats (Fig. 1) . Although strain 2.4N3A showed a strongly reduced virulence in 10-week-old pigs it still caused severe disease or death in 3-day-old seronegative piglets. Therefore, to use this strain as a vaccine, its virulence had to be further reduced. McGregor et al. (1985) have demonstrated that inactivation of the thymidine kinase (TK) gene of PrV attenuates the virus and possibly prevents it from becoming latent. We anticipated that inactivation of the TK gene would also reduce the virulence of strain 2.4N3A. Therefore, we deleted a small part of the TK gene of strain 2.4N3A to obtain a TK-/gI-vaccine strain with defined mutations.
We have shown that the PrV genome can be regenerated in vivo from two contiguous non-overlapping 0000-9417 © 1990 SGM restriction fragments that comprise the complete genetic information of the virus (Quint et al., 1987) . In addition, we observed that recombination of sequences at the ends of the subgenomic fragments could yield small deletions. The small deletions present in the inverted repeats of strain 2.4N3A ( Fig. 1) were in fact generated by such a mechanism (Quint et al., 1987) . We used this mechanism to introduce small deletions in the TK gene of PrV. A recombinant virus was constructed that contained a unique restriction site at a defined position in the 3' end of the viral TK gene. Viable virus was then regenerated by transfection of viral DNA, which had been cut at this unique site, into secondary porcine kidney (PK2) cells.
The TK gene of PrV is located on BamHI fragments 9 and 11 ( Fig. l) (Kit et al., 1985) . The BamHI 11 fragment of PrV was subcloned into plasmid pBR322. Using standard procedures (Maniatis et al., 1982) , we blunted the unique XhoI site of the BamHI 11 fragment by treating it with Klenow DNA polymerase I, then a synthetic EcoRI linker 5' CCGGAATTCCGG 3' (New England Biolabs) was inserted. DNA sequence analysis (Sanger et al., 1977) was used to determine whether clones containing the EcoRI site also contained the expected insertion of 16 nucleotides. Insertion of the linker in the TK gene results not only in a unique restriction site (the PrV genome does not contain EcoRI sites) but also in an out-of-frame mutation.
The calcium phosphate precipitation method (Graham & van der Eb, 1973 ) was used to generate recombinant virus. We purified the BamHI 11 fragment of a subclone that contained the correctly inserted linker from an agarose gel and cotransfected it with 2.4N3A DNA into PK-2 cells. Individual plaques were harvested 20 h after transfection and the virus was tested for replication in mouse L TK-cells in the presence of 50gg/ml bromodeoxyuridine (Summers et al., 1975) and assayed for the incorporation of [3H]thymidine into DNA (Tenser et al., 1983) . One of the recombinant viruses exhibiting the TK-phenotype and containing an EcoRI site at the expected position in the TK gene was selected and was designated strain 706. Viral DNA from strain 706 was cut with EcoRI and transfected into PK-2 cells as described above. DNA from plaque-purified virus was subsequently subjected to restriction enzyme analysis using BamHI/EcoRI, SmaI, SmaI/MluI and SmaI/SalI (Fig. 1) . Although a regenerated EcoRI site was occasionally detected, most viral DNA contained small deletions or insertions. Three mutant strains (designated 769, 775, and 783) were selected for further analysis on the basis of their restriction enzyme digestion pattern.
DNA sequence analysis was used to determine the nucleotide sequence around the mutation site of the three selected strains. These sequences were compared with those of the wild-type strain NIA-3 (Baskerville et al., 1973) and the parent strain 706 (Fig. 2) . The figure shows that, with respect to the NIA-3 sequence, 2 bp were inserted in strain 769, whereas 19 bp were deleted from strain 783 and 1 !6 bp were deleted from strain 775. The origin of the 13 bp sequence in strain 775 is uncle'ar.
To determine whether the deletions affected the expression of the TK gene and distal genes, we used Northern blots to analyse RNA from mock-infected cells and cells infected with several PrV strains. The blots were probed with the BamHI/SalI fragment (0-85 kb) which is specific to the TK gene and with the NIA-3 BamHI 11 fragment (Fig. 1 ). The PrV strains tested showed no significant differences in the transcription of the TK gene and a neighbouring 3' gene (data not shown). We concluded that the mutations introduced into the TK gene blocked its expression by premature termination of translation and not transcription.
Strain 783 was chosen for biological evaluation. First, the immunological potency of the strain was compared with that of its parent strain 2.4N3A and three commercially available vaccine strains, Ingelvac (Boehringer), Omnivac (Kit et al., 1985) and Begonia (Visser & Liitticken, 1989) . In a standardized vaccine experiment (De Leeuw & van Oirschot, 1985) , 10-week-old specificpathogen-free (SPF) pigs were allotted to five groups each containing eight pigs. Each group was inoculated intramuscularly with 105 p.f.u, of one of the virus strains; the fifth group served as an unvaccinated control. Twelve weeks later, the pigs were challenged intranasally with 105 p.f.u, of strain NIA-3. Weight gain curves were determined for each vaccinated group and for the non-vaccinated control group (Fig. 3) . After challenge, the growth of pigs vaccinated with strains 2.4N3A, 783 or Begonia was not markedly retarded. However, the growth of pigs vaccinated with the vaccine strains Ingelvac and Omnivac was retarded for 7 to 9 days, resulting in a weight loss of about 3 kg at day 6 after challenge. The growth of the non-vaccinated control group was strongly retarded until day 14 after challenge.
Strains 783, Ingelvac, Omnivac and Begonia induced similar neutralizing antibody titres. These titres were lower than that induced by strain 2.4N3A (Table 1) . Pigs vaccinated with strains 2.4N3A or 783 had only slight fever, but pigs vaccinated with strains Begonia, Ingelvac, and Omnivac had fever for 1, 2 and 3 days respectively. None of the pigs vaccinated with strains 2.4N3A, 783 and Begonia shed virus, whereas one pig vaccinated with strain Ingelvac and two pigs vaccinated with strain Omnivac shed virus for 2 days. This confirms the observation that neutralizing antibody titres do not necessarily indicate the efficacy of these vaccines (De Leeuw & van Oirschot, 1985) .
As shown in Table 1 , a secondary immune response was measured in all pigs vaccinated with the commercial vaccines. Of the pigs vaccinated with strain 783, only four showed such a response whereas no such response was seen in pigs vaccinated with strain 2.4N3A. Pigs that do not show a secondary antibody response after challenge are considered to be completely protected. We also analysed whether strain 783 can be reactivated. At day 46 after vaccination, four of the six pigs from the virulence test described above were treated with the immunosuppressive drug prednisolone for 4 consecutive days (van Oirschot & Gielkens, 1984) and two sentinel pigs were placed in contact. The pigs were kept under observation until day 70 after vaccination and were then killed. No PrV was detected in the oropharyngeal fluid samples collected daily from all pigs and we could not isolate infectious PrV from organs such as the brain, lung * Challenge results are expressed as the total number of days during which: (i) the mean body temperature of the group (eight pigs) was above 40 °C (fever); (ii) one or more animals shed virus; in this test, only four out of eight animals per group were taken into account; these four animals were monitored daily until day 10 after challenge, by analysing nasal swabs for the presence of infectious virus; (iii) the mean weight of the group was less than the mean weight at the day of challenge.
t Each virus strain was tested in eight pigs; no pig died in any experiment. Geometric mean neutralizing antibody titre at day of challenge is expressed as log~0 of the reciprocal of the final serum dilution inhibiting c.p.e, in 50% of the cultures.
§ Number of animals showing a secondary antibody response after challenge. NA, Not applicable.
and tonsil or from tissue explants of the trigeminal ganglia. No rise in antibody titre was observed in pigs treated with prednisolone and the sentinel pigs remained serologically negative for PrV. We conclude that no reactivation of strain 783 occurred after immunosuppressive treatment. Rziha et al. (1989) were not able to reactivate virus nor detect viral DNA in tissues of pigs vaccinated with strain Begonia. This indicates that Begonia probably does not become latent in tissues of infected pigs. Our findings suggest that the same holds true for strain 783.
To examine the innocuity of strain 783 for sheep and calves, seronegative animals were exposed to a high virus dose. Two groups of four sheep (6 to 7 months old) and calves (4 weeks old) received 107 p.f.u, of virus by the intranasal or intramuscular route. During the observation period (3 weeks following vaccination), no clinical signs suggestive of Aujeszky's disease were observed in any of the animals. These results show that strain 783 is innocuous for calves and sheep. The same was observed for Begonia (Visser & Lfitticken, 1989) . However, whereas all animals vaccinated with 783, except the intranasally inoculated calves, developed virus-neutralizing antibodies against PrV, sheep and calves vaccinated with Begonia did not. This suggests that some replication of 783 virus may have occurred in animals that seroconverted.
Pigs vaccinated with gI-negative PrV strains can be differentiated serologically from pigs infected with wildtype virus (van Oirschot et al., 1986 (van Oirschot et al., , 1988 . Recent data suggest that a programme of intensive vaccination with gI-negative vaccines combined with culling of gIseropositive pigs can be successful in controlling and eradicating PrV (van Oirschot & de Waal, 1987; van Oirschot & Wijsmuller, 1988; Engel & Wierup, 1989) . Because the gI gene has been deleted, strain 783 does not express gI. This property, plus its safety and efficacy, make strain 783 a promising vaccine for application in PrV eradication programmes.
